CAS 66335-38-4
:5′-Deoxy-5-fluorocytidine
Description:
5′-Deoxy-5-fluorocytidine, with the CAS number 66335-38-4, is a nucleoside analog that features a fluorine atom substituted at the 5-position of the pyrimidine ring of cytidine. This modification enhances its potential as an antimetabolite, particularly in the context of cancer therapy, as it can interfere with DNA synthesis and function. The compound is characterized by its ability to mimic natural nucleosides, allowing it to be incorporated into DNA during replication. Its structure includes a ribose sugar moiety, which is essential for its biological activity. 5′-Deoxy-5-fluorocytidine exhibits properties typical of nucleosides, such as solubility in polar solvents and stability under physiological conditions, although it may be subject to enzymatic degradation. The fluorine substitution alters its biochemical interactions, making it a subject of interest in research focused on targeted therapies for various malignancies. Overall, this compound represents a significant area of study in medicinal chemistry and pharmacology, particularly in the development of novel anticancer agents.
Formula:C9H12FN3O4
InChI:InChI=1/C9H12FN3O4/c1-3-5(14)6(15)8(17-3)13-2-4(10)7(11)12-9(13)16/h2-3,5-6,8,14-15H,1H3,(H2,11,12,16)/t3-,5+,6?,8-/m1/s1
InChI key:InChIKey=YSNABXSEHNLERR-ZIYNGMLESA-N
SMILES:O[C@H]1[C@@H](O[C@H](C)[C@H]1O)N2C(=O)N=C(N)C(F)=C2
Synonyms:- 5'-Deoxy-5-Fluoro Cytidine
- 5'-deoxy-5-fuluro-D-cytidine
- 5-Deoxy-Fluorocytidine
- 5-Fluoro-5'-deoxycytidine
- 5′-Dfcr
- Cytidine, 5′-deoxy-5-fluoro-
- 5-deoxy-5-fluorocytidine
- 5'-Deoxy-5'-Fluorocytidine
- 5′-Deoxy-5-fluorocytidine
- 5'-Deoxy-5-fluoro-D-cytidine
- 5-Fluoro-5’-deoxycytidine, 5’-DFCR
- See more synonyms
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 15 products.
5'-Deoxy-5-fluorocytidine
CAS:Formula:C9H12FN3O4Purity:>98.0%(T)(HPLC)Color and Shape:White to Almost white powder to crystalMolecular weight:245.21Capecitabine Related Compound A (5'-deoxy-5-fluorocytidine)
CAS:Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds, nesoiFormula:C9H12FN3O4Color and Shape:Off-White PowderMolecular weight:245.081185'-Deoxy-5-fluorocytidine
CAS:Formula:C9H12FN3O4Purity:97%Color and Shape:SolidMolecular weight:245.2077Capecitabine EP Impurity A (Capecitabine USP Related Compound A)
CAS:Formula:C9H12FN3O4Color and Shape:White To Off-White SolidMolecular weight:245.215'-Deoxy-5-fluorocytidine
CAS:<p>5'-Deoxy-5-fluorocytidine</p>Purity:≥98%Molecular weight:245.21g/mol4-Amino-1-(5-deoxy-β-D-ribofuranosyl)-5-fluoropyrimidin-2(1H)-one (5'-Deoxy-5-fluorocytidine)
CAS:Color and Shape:Neat5'-Deoxy-5-fluorocytidine
CAS:<p>5'-Deoxy-5-fluorocytidine is an intermediate metabolite of the DNA synthesis inhibitor capecitabine.</p>Formula:C9H12FN3O4Purity:99.67%Color and Shape:White SolidMolecular weight:245.215’-Deoxy-5-fluorocytidine-13C,15N2
CAS:Controlled Product<p>Applications A labelled metabolite of Capecitabine.<br></p>Formula:C813CH12FN15N2O4Color and Shape:NeatMolecular weight:248.195'-Deoxy-5-fluorocytidine
CAS:<p>5'-Deoxy-5-fluorocytidine is a cytosolic nucleoside analogue that is phosphorylated by cellular enzymes to the active form 5'-deoxy-5-fluorouridine monophosphate. It is a prodrug, which is activated in the body to release 5-FU and inhibits the growth of cancer cells. 5'-Deoxy-5-fluorocytidine has been shown to be effective against metastatic colorectal cancer in humans and resistant breast cancer in mice. The drug can also be used as an oral prodrug for 5-FU, which has a wide therapeutic index and low toxicity. Studies have shown that it selectively inhibits proliferation of solid tumours through inhibition of protein synthesis and cell division. The drug also has antiangiogenic effects, which are thought to contribute to its antitumor activity.</p>Formula:C9H12FN3O4Purity:Min. 98 Area-%Color and Shape:White PowderMolecular weight:245.21 g/mol5′-Deoxy-5-fluorocytidine
CAS:Formula:C9H12FN3O4Purity:98%Color and Shape:Solid, White to almost white powderMolecular weight:245.21













